Benjamin Dach focuses his practice on patent litigation and intellectual property law, with a specific emphasis on Hatch-Waxman litigation, counseling and patent prosecution related to the life sciences, branded drug and pharmaceutical, biotechnology, chemical and medical device fields.
Benjamin is involved in trials and post-grant patent proceedings before the USPTO’s Patent Trial and Appeal Board (PTAB) (formerly the Board of Patent Appeals and Interferences), including patent interferences, inter partes reviews, post-grant reviews and ex parte patent appeals, as well as ex parte reexamination proceedings. Benjamin brings deep knowledge and a unique background in the chemical, biological and pharmaceutical fields that allows him to creatively leverage his clients’ innovations and implement practical solutions to achieve best-case scenarios for his clients.
Benjamin has extensive experience in all stages of patent litigation, including fact discovery, document production, expert discovery and reports, and preparing depositions, motions and briefs. In particular, he helps clients anticipate and mitigate IP risks and provides patent prosecution in order to maximize protection and value for his clients' innovations. He regularly conducts patents searches and due diligence on intellectual property portfolios concerning the patentability of inventions, patent validity and the freedom-to-operate new technologies, including vaccines for COVID-19.
- Fordham University School of Law, J.D.
- Columbia University, Ph.D.
- Yeshiva University, B.A., magna cum laude
- New York
- New Jersey
- United States Patent and Trademark Office